Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
By Leah Sherwood, Rashmi Kanagal-Shamanna, MD - Last Updated: February 27, 2023Rashmi Kanagal-Shamanna, MD, of the MD Anderson Cancer Center, discusses the optical genome mapping platform and the clinical implications the technology will have for patients with acute myeloid leukemia and myelodysplastic syndromes.
Advertisement
Advertisement
Related Posts
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in AML.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.